Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy Adults
Frances Priddy(International AIDS Vaccine Initiative), Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michelle Lally(Brown University), Michael Marmor(New York University), John W. Shiver(IGM Biosciences (United States)), Devan V. Mehrotra(United States Military Academy), P.P. Kulkarni(United States Military Academy), James G. Kublin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Erin Quirk(Gilead Sciences (United States)), Kathleen Monahan(United States Military Academy), Lisa Kierstead(United States Military Academy), Sheri Dubey(United States Military Academy), Mark J. DiNubile(Io Therapeutics (United States)), David P. Wright, Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deborah D. Brown(United States Military Academy), Richard M. Novak(Northwestern University), Stephen J. Brown(AIDS Research Alliance), Danilo R. Casimiro(Institut Mérieux (France)), Jacob Lalezari(Quest Clinical Research (United States)), Steven Santiago(Care Resource)
Cited by 246
Related Papers
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
|Science|1993|2.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k